CTOs on the Move

Infinity Pharmaceuticals

www.infi.com

 
Infinity Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.infi.com
  • 780 Memorial Dr
    Cambridge, MA USA 02139
  • Phone: 617.453.1000

Executives

Name Title Contact Details

Funding

Infinity Pharmaceuticals raised $20M on 01/09/2020
Infinity Pharmaceuticals raised $92M on 02/12/2021

Similar Companies

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Florida Hospital Orlando

Florida Hospital Orlando is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxford Instruments PLC

Oxford Instruments PLC is a Carteret, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enzymotec

Enzymotec develops and manufactures nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies. Since its establishment in 1998, the company has enjoyed accelerated growth, generating impressive sales worldwide, by launching a diverse portfolio of innovative products. Our two business segments leverage our lipid-related expertise: Nutrition and Pharma.   Enzymotec's diverse range of products span the entire human life-cycle - from infancy to old age, providing key ingredients for use in infant formula and nutritional supplements, as well as branded medical foods.   Enzymotec's multi-disciplinary team, including scientists, engineers and business development professionals, have an outstanding track-record in turning advanced lipid science into commercially attractive, nutritional solutions, constantly enriching our unique cluster of technology and expertise.

Bamboo Therapeutics

Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.